Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 27, 2026

Banner|Aetna Brings Community Together for 2026 Phoenix Heart Walk

View original at finance.yahoo.com
Banner|Aetna Brings Community Together for 2026 Phoenix Heart Walk Arizona health plan continues its longstanding support of cardiovascular research and prevention at the Phoenix Heart Walk PHOENIX, March 27, 2026--(BUSINESS WIRE)--Banner|Aetna, an Arizona-based health plan offering integrated coverage and care through…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Heart disease has impacted my family, so this work is personal. My dad had his first heart attack while I was in college, and it was a wake-up call.

    60% confidence

  • Banner|Aetna employees show up year after year because the mission matters, reflecting commitment to the communities they serve

    60% confidence

  • Banner|Aetna's impact is powered by its people

    60% confidence

  • The Heart Walk promotes research and education to help people live longer, healthier lives

    60% confidence

  • Banner|Aetna is committed to supporting people living with cardiovascular disease and the families who care for them through access to quality care, prevention, and resources

    60% confidence

  • Heart disease and stroke are still among the leading causes of death and disability in the U.S., and the Heart Walk helps fuel the work that saves lives

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com